Pharming Group NV announced the appointment of Dr. Perry Calias as the company's Chief Scientific Officer, with immediate effect. Dr. Calias will have overall responsibility for the Company's new Enzyme Replacement Therapy programs, achieving the scientific milestones set in the business plan, enhancing the IP portfolio, overseeing new product development and contributing to the overall strategic direction of the company.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.796 EUR | -3.22% | -4.33% | -22.79% |
11:58am | Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug | MT |
21/05 | Transcript : Pharming Group N.V. - Shareholder/Analyst Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.79% | 601M | |
+39.82% | 734B | |
+31.94% | 591B | |
-7.31% | 350B | |
+14.23% | 315B | |
+0.86% | 276B | |
+13.98% | 238B | |
-6.34% | 204B | |
+8.31% | 206B | |
+4.51% | 161B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- Pharming Group NV Appoints Perry Calias as Chief Scientific Officer